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ABSTRACT
Chemotherapy fails to cure most cancer patients with
advanced disease, particularly patients with the most
common forms of solid tumors. The presence or develop-
ment of resistance to anticancer agents is the major cause
of this failure. Several of the mechanisms underlying drug
resistance to cytotoxic drugs have been elucidated in the
last two decades, largely by employing in vitro drug-
selected cancer cell lines. In unselected cell lines and prob-
ably also in human cancer, multiple mechanisms are
redundantly present to defend the organism from the
insults of drugs. Mechanisms have been unraveled by
which cross-resistance ensues to multiple drugs (multidrug
resistance), similar to what is commonly seen in patients.
More recently, the identification of downstream genes,
intimately involved in cell-cycle checkpoints, appears also
to directly contribute to determining the sensitivity to cyto-
toxic drugs by regulating the response of the cell to the
drug damage. The identification of mechanisms of drug
resistance has provided ways of attempting to revert the
drug resistance. Although, so far, attempts to revert P-gly-
coprotein-mediated multidrug resistance have only sorted
out limited efficacy, new drugs and new strategies are
being devised and implemented, such as high-dose
chemotherapy and gene transfer. The Oncologist 1996;1:82-87
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INTRODUCTION
The presence or development of resistance to anticancer
drugs is the main cause of failure of chemotherapy in the
majority of the most common forms of cancer (e.g., lung,
colon, breast). Resistance to chemotherapeutic drugs can be
already present at diagnosis or it can develop after treatment
with chemotherapy. These two forms of drug resistance are
respectively called intrinsic and acquired. It is unknown
whether the underlying mechanisms of drug resistance are
the same in these two forms of drug resistance.
Many causes of drug resistance are well recognized, such
as those due to administration of inadequate doses or sched-
uling of the drug, or to altered pharmacokinetics, or to limited
penetration of the drug into the tumor. Limited penetration
may be caused by poor vascularization, or extensive necrosis
of parts of the tumor. It can also be due to localization of the
tumor in areas of the body which are difficult to reach (sanc-
tuary sites) because of the presence of a tissue-blood barrier
(e.g., blood-brain, blood-testis, placenta).
A well-known reason for poor sensitivity to chemotherapy
is the slow growth kinetics of the tumor; in fact, most known
anticancer agents exquisitively act on proliferating cells.
Research on drug resistance in the last two decades has
focused primarily on the study of cellular mechanisms of
drug resistance. Whether these are more important than
physical mechanisms or drug-related mechanisms is still
rather unclear, and numerous examples of both cases are
present in the literature.
CELLULAR DRUG RESISTANCE
The establishment of cancer cell lines which are in vitro-
selected resistant by exposure to increasing concentrations of
anticancer agents has made
possible the identification 
of a number of mecha-
nisms of cellular drug
resistance. The cell clones
that survive in culture in
the presence of escalating
concentrations of drug can
be analyzed, and alter-
ations at biochemical and/or
genetic levels identified.
Several biochemical
causes of drug resistance
have been described for
exposure to several drug
types and are summarized
in Table 1. Some drugs,
such as methotrexate, are
transported into the cell
Table 1. General mechanisms
leading to cellular drug resistance
 Decreased drug uptake
 Increased drug extrusion
 Decreased drug activation
 Increased drug inactivation
 Decreased formation of 
drug-target complexes
 Increased repair of drug 
damage
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through a high-affinity transport system; a loss of, or
reduced activity of, this system may induce resistance.
There are now at least two well-known cell mem-
brane proteins which can extrude a number of drugs from
the cell and cause multidrug resistance (MDR); this
mechanism is extensively described later in the text.
Obviously, a reduced uptake or an increased efflux will
lower the intracellular concentration of the drug, thereby
diminishing its activity.
Some anticancer agents require metabolic activation in
the body, such as the alkylating agent cyclophosphamide; an
alteration of the metabolic conversion (e.g., loss of deoxycy-
tidine kinase activity for Ara-C activation) can lead to
reduced activity of the drug. A mechanism of this sort has
also been recently described for the new camptothecin ana-
log Irinotecan (CPT-11), a DNA topoisomerase I inhibitor,
which requires conversion to the active metabolite SN-38 in
order to exert antitumor efficacy. This conversion is cat-
alyzed by carboxyestherase, an enzyme present in several
cell types. Reduced levels of this enzyme have been observed
in cell lines resistant to CPT-11 as a possible cause of drug
resistance. Of course, this mechanism is difficult to extrapo-
late to the in vivo situation, where, in fact, the conversion
will occur very rapidly after intravenous administration and
the tumor will be exposed directly to SN-38, bypassing the
need for activation of CPT-11 in the tumor cells.
Drug inactivation is also a well-described mechanism of
drug resistance, such as the one due to increased glutathione-
S-transferase activity in resistance to alkylating agents.
Decreased formation of drug-target complexes can
occur in one of several different ways: 1) an amino acid sub-
stitution in the target enzyme determines a decreased affin-
ity of the enzyme for the drug; 2) overproduction of the
target enzyme, making impossible a complete inhibition; 3)
an increased level of normal substrate competes with the
drug for the target enzyme; and 4) a decrease of essential
cosubstrates reduces the formation of the complex. More
than one of these mechanisms are implicated in resistance to
the antimetabolites methotrexate and 5-fluorouracil. Finally,
an increased repair of damage produced by the drug can also
lead to resistance (e.g., increased repair of DNA damage
induced by alkylating agents or topoisomerase inhibitors).
Genetic analysis of cell lines selected for resistance to
anticancer drugs has shown that various genetic alterations
can ensue in these cells [1]. The mutation rate is usually low
in a normal cell population, but it can increase by exposure
to mutagenic agents. Drug resistant mutants have been
hypothesized to appear with a frequency of 10–6 cell divi-
sions. Large tumors have a greater chance of developing
mutants which are drug resistant because more duplications
will have occurred. This may be an additional reason why,
in general, large tumor masses are less sensitive to eradica-
tion by chemotherapy. Several different types of biochemi-
cal changes leading to drug resistance are associated with
gene alterations, such as mutations or amplifications of genes
involved in resistance to specific drugs. Mutations in a gene
can lead to decreased production of a protein, synthesis of an
unstable or nonfunctional protein, production of a protein
with altered drug affinity (often caused by point mutations),
or increased production of a normal protein. This last alter-
ation is, however, caused mainly by transcriptional activa-
tion or gene amplification in the absence of mutations.
Multiple pathways and different mechanisms of action
have been described for a number of drugs, but in particu-
lar for antimetabolites. It is therefore not surprising that
tumor cells can present many mechanisms of drug resis-
tance to a single drug. As an example, resistance to the
antimetabolite methotrexate can occur through decreased
activity of the membrane transport system, decreased
polyglutamation of methotrexate, alteration or increased
production of dihydrofolate reductase, decreased levels of
thymidilate synthase, or increased nucleoside salvage.
Although one specific mechanism is usually overwhelming,
multiple mechanisms can coexist in the same cell line.
All of the above-mentioned mechanisms have been pri-
marily described in in vitro-selected cell lines, whereas much
less is known about the mechanisms of resistance and differ-
ential sensitivity to drugs of unselected cell lines. In general,
it would appear that the process of selection drives the cells,
in a rather extreme fashion, to develop mechanisms to escape
death; it is dubious whether these same mechanisms are in
place or expressed at comparable levels in unselected cell
lines as in in vitro-selected resistant cell lines. This is, of
course, a matter of great concern, as drug exposure in
patients is rather different from that obtained in vitro. Whether
in vitro findings at all reflect the basis of drug resistance at the
cellular level in the patient remains to be elucidated.
MULTIDRUG RESISTANCE
Although in patients, resistance to one drug does not
necessarily always imply resistance to other drugs, this is
quite often the case. This may partly be due to the present
use of combined chemotherapy programs for the treatment
of most forms of cancer, but also likely to the presence of
broad drug resistance to multiple anticancer drugs with no
common mechanism of drug action.
By exposing cells in vitro to one drug, clones may be
selected which display resistance mechanisms to the single
drug or class of drugs, but cells can also simultaneously
become resistant to several anticancer drugs not belonging
to the same type. This phenomenon is called cross-resis-
tance and mirrors the clinical setting where patients who
have become resistant to the first chemotherapy are very
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frequently also resistant to the second chemotherapy,
regardless of whether the drugs employed are different by
mechanism of action or chemical class.
The best characterized of this type of drug resistance has
been called multidrug resistance. MDR is the in vitro resis-
tance induced by exposure to a drug, which leads to cross-
resistance to a number of other drugs which are not related
by chemical structure or mechanism of action. MDR is due
to overexpression of P-glycoprotein, a cell membrane pro-
tein of 170 kDa molecular weight (P-170) [2]. The anticancer
drugs involved in this phenotype are natural products such
as anthracyclines, Vinca alkaloids, epipodophyllotoxins,
actinomycin D and taxanes.
P-170 is a transmembrane protein present in tumor and
normal cells and is responsible for the active transport of
anticancer agents and possibly several other physiological
substances from the cytosol of the cell to the extracellular
space. By active drug extrusion, the drug concentration at
the intracellular target site is insufficient, thereby resistance
occurs. P-170 is encoded by the MDR-1 gene. From the
amino acid sequence of the protein it is hypothesized that
P-170 consists of two similar halves, each containing six
transmembrane domains and an ATP binding site; the trans-
membrane segments probably form a channel through
which the drug can be extruded [3].
P-170 expression occurs in cells of several normal tis-
sues, such as adrenal cortical cells, apical surface of intesti-
nal epithelium, a small percentage of biliary canaliculi,
some CD34+ cells, brush border of proximal tubules of the
kidney, pancreas excretory ducts, and endothelial cells of
brain, testicles and placenta. The latter localizations provide
evidence for the presence of the blood-tissue barrier in these
organs, which is also likely responsible for the difficult pen-
etration of most of the cytotoxic drugs into those organs.
The other localizations in normal tissue are consistent with
a functional extrusion of toxins from the organism, steroid
transport in the case of adrenals, and defense mechanism in
CD34+ bone marrow cells [4].
A number of tumors overexpress the MDR-1 gene;
among these are: neuroblastoma, rhabdomyosarcoma,
myeloma, non-Hodgkin’s lymphomas, colon carcinoma,
breast carcinoma and renal cell cancer. Several tumor types
with high MDR-1 expression actually derive from tissues
which have a high expression of the gene (e.g., colonic epithe-
lium). Expression of the MDR-1 gene has been shown to
increase after exposure to chemotherapy on several occasions
[5], but whether this increase is responsible for enhanced
resistance to anticancer agents or is simply a feature of a more
malignant phenotype is still a matter of discussion [5-8].
A number of cell lines have been described with
cross-resistance patterns which are very similar to those of
P-170-mediated MDR, but in which MDR-1 is not overex-
pressed. These other MDR phenotypes have been generi-
cally identified as non-P-glycoprotein-mediated MDR.
Recently, another drug transport protein has been identified,
called MRP, or multidrug resistance-associated protein,
which, like P-glycoprotein, is localized mainly on cell mem-
branes [9]. The MRP gene is overexpressed and amplified in
a number of cell lines which were selected in vitro for resis-
tance to doxorubicin. These cell lines lack expression of the
MDR-1 gene. The patterns of cross resistance are very sim-
ilar, although paclitaxel does not seem to be a substrate of
MRP, whereas it is for P-170 [10].
Both MRP and MDR-1 genes belong to the ATP-binding
cassette superfamily of transporter proteins which can trans-
port a number of different substrates from drugs to peptides
to ions [11]. Actually, the MRP gene sequence is much closer
to the cystic fibrosis and other genes encoding for transport
proteins, than to the MDR-1 and MDR-3 genes. As with the
MDR-1 gene, transfection experiments can induce MDR in
cells transfected with the MRP gene. Recently, the MRP gene
product has been shown to be a primary-active ATP-depen-
dent export pump for conjugates of lipophilic compounds
with glutathione and several other anionic residues [12], sug-
gesting that MRP overexpression can cause MDR by pro-
moting the export of drug modification products from cells
[13]. Whether overexpression of the MRP gene is of clinical
importance is a matter of current investigation.
More recently, another gene has been cloned and identi-
fied which might be responsible for yet other forms of non-
P-glycoprotein-mediated MDR. The gene product is targeted
by a monoclonal antibody called LRP56 (Lung Resistant
Protein), because it was identified in a lung cancer cell line.
Overexpression of LRP56 has been observed in in vitro-
selected resistant lung cancer cell lines, mainly after expo-
sure to anthracyclines [14]. Interestingly, there is no analogy
between the LRP gene and the ATP-binding cassette super-
family of transporter proteins, and the gene appears to be the
human major vault protein [15]. This 110 kDa protein is one
of a complex of four proteins and RNA which is found in the
nucleopore complex and in cytoplasmic organelles [15]. This
localization points to a possible role of LRP in intracytoplas-
matic trafficking and trapping of cytotoxic drugs (Fig. 1).
The overexpression of this protein is more frequently
present in tumors which are intrinsically resistant to
chemotherapy than in tumors that can be cured by
chemotherapy [16]. Furthermore, ovarian cancer patients
whose tumors had higher LRP expression had poorer
response to cisplatin-containing chemotherapy and shorter
progression-free survival and overall survival [17].
Additional clinical studies investigating the expression of
the LRP gene are in progress and results are awaited.
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Finally, another type of non-P-glycoprotein-mediated
MDR, also called atypical MDR, is due to alterations of the
function of the enzyme DNA topoisomerase II and concerns
cross-resistance between drugs which are targeted to the
enzyme. DNA topoisomerase II is an essential nuclear enzyme
which catalyzes conformational changes of DNA, important
for several steps of DNA metabolism such as transcription,
DNA synthesis, chromosome segregation, and recombination.
The conformational modifications are rendered possible by
formation of a transient double DNA break, followed by a
DNA strand passage and eventually by relegation. Inhibitors
of topoisomerase II prevent the relegation process from occur-
ing by freezing the so-called “cleavable complex” formed
between the enzyme and DNA. DNA topoisomerase II-tar-
geted drugs are anthracyclines, anthracenediones, epipodo-
phyllotoxins, actinomycin D and amsacrines. The drugs
involved in MDR due to alteration of topoisomerase II are
essentially the same drugs involved in the P-170-mediated
MDR, with the exception of Vinca alkaloids and taxanes [18].
The reduced activity of the enzyme and/or reduced expression
of the gene have been identified as responsible for the
decreased chemosensitivity to topoisomerase II inhibitors in
cell lines which had been selected by exposure to several
topoisomerase II-targeted drugs. Nevertheless, a good corre-
lation between activity/expression and antitumor efficacy
could also be found in unselected cell lines of various types,
indicating that topoisomerase II-mediated MDR might be
responsible for a more generalized form of drug resistance
than the transport-mediated MDR types [19].
In recent years, some genes involved in response to cell
damage (particularly DNA damage) have also been investi-
gated as possibly responsible for drug resistance. p53 and
bcl-2 are important genes that control programmed cell
death (apoptosis). Tumor cells which have mutant p53 are
less sensitive to a large spectrum of drugs including dox-
orubicin, cisplatin and 5-fluorouracil [20]. Given the fact
that p53 appears to be the gene that most frequently is
altered in human malignancy, these considerations may be
of extreme importance. This is a field in very rapid devel-
opment, and it now appears clear that downstream genes
may play an important role. This new understanding of the
tumor biology opens up new therapeutic possibilities,
including gene therapy.
With the advances in understanding the mechanisms of
drug resistance, it appears more and more clear that within a
given tumor there may well be multiple mechanisms in action.
Figure 1. Schematic representation of the mode of action of the LRP gene product.
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OVERCOMING DRUG RESISTANCE
A large number of trials attempting to revert P-glycopro-
tein-mediated MDR have been performed. Many substances
with drug-resistance-modifying capabilities are known. They
belong to different chemical classes, ranging from beta-block-
ers to anti-arrhythmics, to hormones, to immunosuppressives
(Table 2). Although the mechanism of MDR reversal can be
complex, nearly all reversal compounds are substrates of
P-glycoprotein and compete with the cytotoxic drug for extru-
sion from the cell. The first of these substances to be tested was
verapamil, which unfortunately was found to be extremely car-
diotoxic at doses which give patients plasma concentrations
necessary to revert drug resistance in vitro. More recently,
cyclosporin-A and analogs like PSC-833, which is devoid of
cardiac, renal and immunosuppressive properties, have been
developed and are under clinical investigation.
A large number of phase I and dose-finding studies
have been performed with drug resistance reversal agents
and cytotoxic drugs; however, randomized trials are few.
Despite occasional responses in patients with hematologi-
cal malignancies, and a small positive randomized study of
verapamil added to chemotherapy in untreated non-small
cell lung cancer [21], three large randomized trials failed to
show any benefit of reverters in influencing response to
chemotherapy or survival in refractory patients with multi-
ple myeloma [22], untreated small cell lung cancer [23] and
breast cancer [24].
Some reverters, such as verapamil and cyclosporin A,
including the analog PSC-833, substantially influence the
pharmacokinetics of the anticancer drug possibly by
decreasing their elimination and increasing their plasma
concentration over time by 40%-60%, thereby increasing
their toxicity. Reverters which are active in vitro in revert-
ing P-glycoprotein-mediated MDR appear to have signifi-
cantly less activity in reverting MDR which is due to MRP
overexpression. Other substances that appear to more effi-
ciently block the drug efflux due to overexpression of MRP
rather than of MDR-1 are being investigated [25].
Another approach for reversing or preventing the devel-
opment of drug resistance to anticancer agents is the use of
very high doses of chemotherapy. Many anticancer agents, in
fact, possess a steep dose-response relationship, and higher
doses of a drug have a much higher therapeutic activity in
several tumor types. The recent introduction of colony-stim-
ulating factors and peripheral stem cell infusions into routine
use has replaced, at least in solid tumors, the use of bone mar-
row transplantation, which is complicated by much higher
morbidity and mortality rates. These improvements have
made the administration of high-dose chemotherapy more
feasible by substantially reducing the intensity and length of
myelosuppression. Randomized studies comparing tradi-
tional chemotherapy doses with  high-dose chemotherapy are
ongoing in several tumor types.
Another way of allowing higher doses of chemother-
apy to be administered is to transfect peripheral stem cells
with the MDR-1 gene in order to make them more resistant
to chemotherapy. Clinical studies employing this approach
are also in progress.
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